| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/16/1999 | CA1340445C Diamino-2,4-pyrimidine 3-oxide derivatives and their use for the prevention and treatment of hair loss |
| 03/16/1999 | CA1340444C Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents |
| 03/12/1999 | CA2246928A1 Novel phthalaldehyde derivatives, process for their preparation, and their use |
| 03/11/1999 | WO1999011808A1 Rna respiratory syncytial virus vaccines |
| 03/11/1999 | WO1999011781A1 Recombinant human erythropoietin with advantageous glycosylation profile |
| 03/11/1999 | WO1999011778A1 Antisense treatment of pulmonary hypertension |
| 03/11/1999 | WO1999011753A1 SpoOJ2 OF STAPHYLOCOCCUS AUREUS |
| 03/11/1999 | WO1999011651A2 3-descladinose 6-o-substituded erythromycin derivatives |
| 03/11/1999 | WO1999011649A2 Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| 03/11/1999 | WO1999011647A1 Fused thiophene compounds and medicinal use thereof |
| 03/11/1999 | WO1999011646A1 Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same |
| 03/11/1999 | WO1999011645A1 Poly(adp-ribose) polymerase ('parp') inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 03/11/1999 | WO1999011643A1 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| 03/11/1999 | WO1999011642A1 Aminometyl oxooxazolidinyl benzene derivatives |
| 03/11/1999 | WO1999011637A1 Protease inhibitors |
| 03/11/1999 | WO1999011635A1 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors |
| 03/11/1999 | WO1999011629A1 Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists |
| 03/11/1999 | WO1999011628A1 Alkoxy-substituted compounds, methods, and compositions for inhi biting parp activity |
| 03/11/1999 | WO1999011626A1 Integrin receptor antagonists |
| 03/11/1999 | WO1999011624A1 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| 03/11/1999 | WO1999011620A1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors |
| 03/11/1999 | WO1999011608A1 Malonic acid based matrix metalloproteinase inhibitors |
| 03/11/1999 | WO1999011606A2 Inhibitors of protein tyrosine phosphatase |
| 03/11/1999 | WO1999011605A1 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives |
| 03/11/1999 | WO1999011604A1 Sterilized 5-aminolevulinic acid |
| 03/11/1999 | WO1999011290A1 Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds |
| 03/11/1999 | WO1999011289A1 Remedies for drug addiction |
| 03/11/1999 | WO1999011283A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase |
| 03/11/1999 | WO1999011277A1 Kits and methods for alleviation of lower gastrointestinal disorders in a human patient |
| 03/11/1999 | WO1999011275A2 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
| 03/11/1999 | WO1999011274A1 Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons |
| 03/11/1999 | WO1999011273A1 Use of sulfated oligosaccharides as inhibitors of cardiovascular disease |
| 03/11/1999 | WO1999011271A1 Use of polycyclic steroid compounds for the manufacture of a medicament for the treatment of cystic kidney diseases, vascular infarction, uremia and related conditions |
| 03/11/1999 | WO1999011270A1 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate |
| 03/11/1999 | WO1999011267A1 Pyrazinone thrombin inhibitors |
| 03/11/1999 | WO1999011266A1 Multiple sclerosis remedies |
| 03/11/1999 | WO1999011265A1 Transdermal therapeutic system containing the active substance scopolamine base |
| 03/11/1999 | WO1999011264A1 Il-8 receptor antagonists |
| 03/11/1999 | WO1999011263A1 Combination therapy comprising amlodipine and a statin compound |
| 03/11/1999 | WO1999011262A1 Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
| 03/11/1999 | WO1999011261A1 Granules free of excipients |
| 03/11/1999 | WO1999011260A1 Combination therapy comprising atorvastatin and an antihypertensive agent |
| 03/11/1999 | WO1999011259A1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 03/11/1999 | WO1999011258A1 Lymphocyte function antigen-1 antagonists |
| 03/11/1999 | WO1999011257A1 Improved compositions and methods for the control of smoking |
| 03/11/1999 | WO1999011256A1 L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof |
| 03/11/1999 | WO1999011255A1 Peroxisome proliferator-activated receptor controllers |
| 03/11/1999 | WO1999011253A1 Il-8 receptor antagonists |
| 03/11/1999 | WO1999011252A2 N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain |
| 03/11/1999 | WO1999011251A1 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases |
| 03/11/1999 | WO1999011250A2 Noribogaine in the treatment of pain and drug addiction |
| 03/11/1999 | WO1999011249A2 Use of endipalene in the treatment of psoriasis |
| 03/11/1999 | WO1999011248A1 Improved method for preventing crystal formation in a scopolamine transdermal device |
| 03/11/1999 | WO1999011245A1 A pharmaceutical composition having two coating layers |
| 03/11/1999 | WO1999011244A1 Sustained release drug delivery devices |
| 03/11/1999 | WO1999011242A1 Oral liposomal delivery system |
| 03/11/1999 | WO1999011240A1 Carotenoid microemulsions |
| 03/11/1999 | WO1999011239A1 Method for preparing pharmaceutical formulations |
| 03/11/1999 | WO1999011238A1 Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins |
| 03/11/1999 | WO1999011237A1 Dermatological compositions |
| 03/11/1999 | WO1998056771A3 Piperazine derivatives and their use as anti-inflammatory agents |
| 03/11/1999 | WO1998056360A3 Film-coated tablet for improved upper gastrointestinal tract safety |
| 03/11/1999 | WO1998055512A3 Smad-interacting polypeptides and their use |
| 03/11/1999 | WO1998055507A3 Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and kinase domain |
| 03/11/1999 | WO1998055126A3 Use of anti-inflammatory steroids for the treatment of chronic inflammatory intestinal diseases |
| 03/11/1999 | WO1998052937A3 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
| 03/11/1999 | WO1998050064A3 Adhesion prevention and an endoscopic insufflation system therefor |
| 03/11/1999 | DE19738855A1 Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht Transdermal therapeutic system with contact adhesive reservoir layer and unidirectional elastic backing |
| 03/11/1999 | DE19738643A1 Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase Transdermal therapeutic system with the active ingredient scopolamine |
| 03/11/1999 | DE19738604A1 Use of Na<+>/H<+> exchange inhibitors |
| 03/11/1999 | CA2304117A1 Integrin receptor antagonists |
| 03/11/1999 | CA2303815A1 N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain |
| 03/11/1999 | CA2303476A1 Recombinant human erythropoietin with advantageous glycosylation profile |
| 03/11/1999 | CA2303295A1 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors |
| 03/11/1999 | CA2303280A1 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| 03/11/1999 | CA2303200A1 Oral liposomal delivery system |
| 03/11/1999 | CA2302805A1 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
| 03/11/1999 | CA2302450A1 Il-8 receptor antagonists |
| 03/11/1999 | CA2302409A1 Condensed thiophene compounds and pharmaceutical use thereof |
| 03/11/1999 | CA2302364A1 Il-8 receptor antagonists |
| 03/11/1999 | CA2302361A1 Protease inhibitors |
| 03/11/1999 | CA2302350A1 Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists |
| 03/11/1999 | CA2302248A1 Improved compositions and methods for the control of smoking |
| 03/11/1999 | CA2302243A1 Use of polycyclic steroid compounds for the manufacture of a medicament for the treatment of cystic kidney diseases, vascular infarction, uremia and related conditions |
| 03/11/1999 | CA2302241A1 A new chemical entity (endipalene) in the treatment of psoriasis |
| 03/11/1999 | CA2302168A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase |
| 03/11/1999 | CA2302167A1 Antisense treatment of pulmonary hypertension |
| 03/11/1999 | CA2302154A1 Use of sulfated oligosaccharides as inhibitors of cardiovascular disease |
| 03/11/1999 | CA2302049A1 Kits and methods for alleviation of lower gastrointestinal disorders in a human patient |
| 03/11/1999 | CA2302037A1 Malonic acid based matrix metalloproteinase inhibitors |
| 03/11/1999 | CA2301642A1 3-descladinose 6-o-substituded erythromycin derivatives |
| 03/11/1999 | CA2301520A1 Pyrazinone thrombin inhibitors |
| 03/11/1999 | CA2301325A1 Method for preparing pharmaceutical formulations |
| 03/11/1999 | CA2300850A1 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate |
| 03/11/1999 | CA2298601A1 Inhibitors of protein tyrosine phosphatase |
| 03/11/1999 | CA2296723A1 Combination therapy comprising atorvastatin and an antihypertensive agent |
| 03/11/1999 | CA2294133A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 03/11/1999 | CA2294118A1 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| 03/11/1999 | CA2294110A1 Alkoxy-substituted compounds, methods, and compositions for inhi biting parp activity |
| 03/11/1999 | CA2294074A1 Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same |